[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-elasticity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-elasticity":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,91,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100629312","efficacy-of-a-combined-oral-and-topical-collagen-regimen-compared-to-topical-collagen-or-oral-collagen-regimens-in-women-with-skin-ageing-signs-100629312",false,"NCT07473037","Efficacy of a Combined Oral and Topical Collagen Regimen Compared to Topical Collagen or Oral Collagen Regimens in Women With Skin Ageing Signs","Evaluation of the Efficacy of an in and Out Collagen Routine Versus the Serum Alone and Versus the Oral Supplement Alone in Women With Skin Ageing Signs","Inclusion Criteria:\n\n* Participant having signed an Informed Consent Form (ICF) before any trial related activity is carried out;\n* Female participant;\n* Participant with a Fitzpatrick skin type I to III;\n* Participant aged 45 to 60 years inclusive at the time of signing the ICF;\n* Participant with a BMI ≥20 and \\\u003C 29 kg\u002Fm²;\n* Participant presenting:\n* Cheek firmness score ≥3 and ≤6 on the 10-point scale;\n* Crow's feet wrinkle score ≥2 and ≤4 on the L'Oréal Atlas;\n* Global facial wrinkle score ≥3 and ≤6 on the 10-point scale.\n* Female participant of childbearing potential must use one of the reliable methods of contraception during the investigation and agree not to change it during the study;\n\nA woman is considered of childbearing potential unless she is:\n\n* Postmenopausal for at least 12 months prior to screening visit;\n* Without uterus and\u002For both ovaries;\n* Has been surgically sterile for at least 6 months prior to Screening visit.\n* Participant must agree to use only the designated products\n* Participant willing and able to comply with all study procedures, lifestyle and dietary restrictions, and complete the entire study period\n* Participant affiliated to a health social security system (according to French Law).\n\nExclusion Criteria:\n\n* Participant who is pregnant or who is breast feeding;\n* Participant receiving hormone replacement therapy (HRT).\n* Participant who smokes more than two cigarettes per week;\n* Participant whose alcohol intake exceeds 2 drinks per week;\n* Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;\n* Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastro-intestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;\n* Participant with an history of sleeve or bypass;\n* Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face which could interfere with the study;\n* Participant with history of any severe disease or current condition which, in the opinion of the Investigator would put the participant at risk by participating in the study or would interfere significantly with the evaluation of study results\n* Participant with known or suspected hypersensitivity to any ingredient(s) of the investigational products;\n* Participants having undergone any aesthetic procedures (such as chemical peels, laser treatments, dermabrasions, injections, anti-ageing masks, hair implants, etc.) on the test areas within 6 months prior to the start of the study are excluded.\n* Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);\n* Participant having use systemic corticosteroids, immunosuppressive drugs, or retinoids (oral or topical) within 3 months prior to study enrollment;\n* Only for participants (20 in each group) who are willing to accept skin microbiopsies: The participant who has a contraindication to skin biopsies\n* Participant impossible to contact in case of emergency;\n* Participant with current participation in any other interventional clinical study, based on interview of the Participant;\n* Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;\n* Participant who has been deprived of their freedom by administrative or legal decision, or who is under care of a guardian or legal guardianship, or Participant hospitalized in a medical or social establishment for any reason.","FEMALE","45 Years","60 Years",{"count":20,"type":21},165,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical study is conducted at one study site and in 165 women with visible signs of skin aging. It compares after 13 weeks the benefit of a combined oral collagen supplement and topical collagen serum regimen compared with oral collagen alone and topical collagen serum alone in reducing in women presenting visible signs of skin ageing .",[27,28,29,30,31,32,33,34,35],"Visible Skin Aging Signs","Wrinkles and Folds in Lower Face","Skin Ageing","Skin Elasticity","Skin Firmness","Skin Evenness","Skin Radiance","Skin Smoothness","Skin Density","NOT_YET_RECRUITING","2026-03-11",{"date":39,"type":40},"2026-03-16","ACTUAL",{"date":42,"type":21},"2026-03-15",{"date":44,"type":21},"2026-10-31",{"name":46,"class":47},"Vichy Laboratoires","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":90},"100604618","clinical-investigation-on-a-polynucleotide-based-device-used-to-improve-skin-hydration-100604618","NCT07151859","Clinical Investigation on a Polynucleotide-based Device Used to Improve Skin Hydration","A Pre-market, Two-stages, Monocentric, Interventional, Single-arm, Clinical Investigation to Evaluate the Safety and the Performance of PN30 (RDM16) for the Improvement of Skin Hydration","Inclusion Criteria:\n\n1. Subject Informed consent form (ICF) signed;\n2. Female and male Subjects aged 18-70 years;\n3. Subjects desiring improvement of skin hydration in maximum 1 area of the face or desiring improvement of skin hydration of neck or décolleté.\n4. Healthy skin;\n5. Willingness to discontinue all dermatological treatment and procedures during the study;\n6. Willingness to follow all study procedures, including attending all site visits, tests and examinations;\n7. Agreeing to present at each study visit without face\u002Fneck\u002Fdécolleté cosmetics;\n8. Accepting to not change their habits regarding food, physical activity, face\u002Fneck\u002Fdécolleté cosmetics and cleansing products;\n9. Willingness to follow indications to avoid make-up in the 12 hours following the injection treatment and to avoid any prolonged exposure to the sun, UV rays and temperatures below 0°C, as well as any sauna or hammam sessions at least until the wheals have been fully reabsorbed;\n10. Skin phototype I-IV according to Fitzpatrick's classification.\n\nExclusion Criteria:\n\n1. Other - different - clinical conditions of the skin (i.e. rosacea, psoriasis, vitiligo, active eczema, severe scleroderma, severe acne and diagnosticated cancer with\u002Fwithout ongoing antitumor therapy);\n2. Infectious or inflammatory processes near the area of intervention;\n3. Presence of cutaneous disease on the tested area, as malformations and recurrent facial\u002Flabial herpes;\n4. Presence of tendon, bone or muscular implants near the area of intervention;\n5. Ongoing cutaneous allergies;\n6. Allergy or contraindications to device components;\n7. Concomitant intake of anticoagulant or antiplatelet medications;\n8. Subjects who have not followed a washout period of 2 weeks from topical corticosteroids, antibiotics, benzoyl-peroxide, azelaic acid, hydroxy acids, topical retinoids;\n9. Immune system illnesses\u002Fdisease;\n10. Uncontrolled diabetes mellitus or uncontrolled systemic diseases (endocrine, hepatic renal, cardiac, pulmonary, neurological disorder);\n11. Treatment with substances which act on blood fluidity (eg. Aspirin, NSAIDs, Vitamin E), or drugs able to influence the test results in the investigator opinion, within 5 days prior to study inclusion;\n12. Known drug and\u002For alcohol abuse;\n13. Mental incapacity that precludes adequate understanding or cooperation;\n14. Any previous permanent and non-permanent cutaneous treatment for aesthetic correction (biomaterial implant, lifting, laser, botulinum toxin injections, chemical peeling, fillers) of the treated area within 6 months prior to study inclusion;\n15. Pregnancy or breastfeeding;\n16. Participation in another investigational study within 1 month prior to study inclusion.",true,"ALL","18 Years","70 Years",{"count":60,"type":21},43,[24],"Adequate skin hydration is critical for maintaining healthy skin. Moreover, dehydration, together with reduction in cell renewal, loss of radiance, elasticity and firmness, is involved in skin aging. Injectable anti-aging products have been widely used for aesthetic improvement of the skin.\n\nIn recent years, new filler products made from High Purification Technology Polynucleotides (PN HPTTM) have been developed and are now being used in Europe. PN HPTTM has a consolidated utilization in the aesthetic field and recently, specific guidelines in their utilization have been implemented. Polynucleotides (PNs) are polymeric chains formed by purines, pyrimidines, deoxyribonucleotides, and deoxyribonucleosides that can be found in cells throughout the human body. PNs have viscoelastic properties and the capability to bind, reorganize and orientate a high concentration of water molecules, creating 3D gel that undergoes an enzymatic cleavage.\n\nOn this basis, polynucleotide-containing products act as short-time temporary fillers to produce a volumizing effect and exert a lubricant and moisturizing action, due to the high concentration of water molecules. Moreover, they maintain for a long time the moisturizing and viscoelastic effect.\n\nA recent report which summarizes the findings and recommendations issued from the Italian Scientific Board of aesthetic physicians, supports the use of PN-HPT.\n\nIn this context, the Sponsor has developed PN30, a soft-tissue filler containing PN-HPT (at a concentration of 30 mg\u002F mL) as functional ingredients which help improve skin turgor and elasticity due to their moisturizing and viscoelastic properties.\n\nPN30 is a new device with no history of marketing but based on a similar product CE marked developed and sold by the Manufacturer with less amount of PN (2%). Therefore, the aim of this pre-market, twostages, monocentric, interventional, single-arm, clinical investigation is to evaluate the safety and the performance of PN30 (RDM16) for the improvement of skin hydration. The clinical investigation is planned as an adaptative two-stages study.\n\nThe planned procedures will be the same for both stages. The primary objective\u002Fendpoint of STAGE I will be to evaluate the safety, while the primary objective\u002Fendpoint of STAGE II will be to evaluate the performance of the device.",[64,65,30,66,67],"Aesthetic Improvement of the Skin","Skin Hydration in Healthy Volunteers","Skin Turgor","Subject Satisfaction",[69,70,71,72,73,74,75,76,77,78,79],"aesthetic","Polynucleotides","PN HPT","skin","skin quality","skin elasticity","skin turgor","skin hydration","face","neck","décolleté","RECRUITING","2026-01-30",{"date":83,"type":40},"2026-02-03",{"date":85,"type":40},"2025-09-18",{"date":87,"type":21},"2027-03-31",{"name":89,"class":47},"Mastelli S.r.l",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":56,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":104,"conditions":105,"keywords":113,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100582895","phase-1-autologous-adipose-cells-therapy-100582895","NCT06869252","Autologous Adipose Cells Therapy","Inclusion Criteria:\n\n1. Outpatients who express interest in skin rejuvenation, and\u002For who are experiencing skin conditions, such as winkles, fine lines, loss of skin elasticity, skin pigmentation, scarring.\n2. Outpatients who are experiencing hair loss or hair thinning\n3. Provision of signed and dated informed consent form\n4. Clearly stated willingness to comply with all the procedures of the study and availability of the study\n5. Female and Male aged between 21 to 80 years old 6 Medical clearance by family doctor\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Known allergic reaction to components of cell culture media\n3. Chronic disease , e.g. cardiovascular disease, diabetes, chronic kidney disease, seizures\n4. Chronic infections, e.g. skin fungi infection, psoriasis\n5. Chronic wound healing\n6. Currently taking hormone therapy\n7. History of cancers and active cancers\n8. Viral infection, e.g. HIV, hepatitis B, influenza, coronaviruses.","21 Years","80 Years",{"count":100,"type":21},40,[102,103],"PHASE1","PHASE2","Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.",[106,107,108,109,30,110,111,112],"Hair Loss\u002FBaldness","Wrinkle Appearance","Volume","Fine Lines","Hair Thinning","Skin Pigmentation","Skin Texture",[114,115],"Adipose Cells","Adipocytes","2025-05-30",{"date":118,"type":40},"2025-05-31",{"date":120,"type":21},"2025-08-01",{"date":122,"type":21},"2026-02-01",{"name":124,"class":47},"CERM INC.",2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":18,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":90},"100589789","effects-of-quantum-probe-for-skin-rejuvenation-and-subdermal-retraction-in-patients-undergoing-high-definition-liposculpture-100589789","NCT06958978","Effects of QUANTUM Probe for Skin Rejuvenation and Subdermal Retraction in Patients Undergoing High-Definition Liposculpture","Quantum001","Inclusion Criteria:\n\n* Patients undergoing body contouring procedures (liposuction or liposculpture), either individually or combined with a maximum of two other major aesthetic procedures involving face, breast, or dermolipectomy.\n* Healthy patients without underlying comorbidities (classified as ASA≤II)\n\nExclusion Criteria:\n\n* Pregnant patients, patients planning to get pregnant, or in breastfeeding stage\n* Past medical history of any collagen disease or autoimmune conditions, including lupus, scleroderma, connective tissue disorders, rheumatoid arthritis, or multiple sclerosis.\n* Past medical history of skin disease including active skin infections, dermatitis, or history of keloid formation.\n* Patient with any metal implants or pacemakers\n* BMI ≥ 32 kg\u002Fm2.",{"count":134,"type":21},80,[24],"This prospective study aims to evaluate the safety and effectiveness of Quantum, a fully internal bipolar radiofrequency probe, for the treatment of prominent skin laxity, providing patients with a more toned and youthful appearance, in patients undergoing High-Definition (HD) Liposculpture.\n\nThe main questions this study seeks to answer are:\n\n* Does Quantum reduce skin laxity in patients undergoing HD Liposculpture?\n* Is the effectiveness in skin laxity reduction influenced by demographical factors, including age, gender, and phototype?\n\nThe participants will be adult patients (between 18-60 years) undergoing HD Liposculpture, with any measurable degree of skin laxity. The participants can not be pregnant, have history of scaring\u002Fhealing problems, autoimmune diseases, severe dermatological conditions, have metal implants, be obese, or have important comorbidities.",[138,139,140,30,31,141],"Skin Laxity","Skin Tightening","Body Contouring Surgery","Liposuction",[143,144,145,146,141,147,148],"Quantum","Quantum RF","Elastometer","Body contouring","Liposculpture","High Definition Liposculpture","2025-04-27",{"date":151,"type":40},"2025-05-06",{"date":153,"type":40},"2024-02-01",{"date":155,"type":21},"2026-06",{"name":157,"class":158},"Total Definer Research Group","OTHER"]